Literature DB >> 23553671

Gene and cell-mediated therapies for muscular dystrophy.

Patryk Konieczny1, Kristy Swiderski, Jeffrey S Chamberlain.   

Abstract

Duchenne muscular dystrophy (DMD) is a devastating muscle disorder that affects 1 in 3,500 boys. Despite years of research and considerable progress in understanding the molecular mechanism of the disease and advancement of therapeutic approaches, there is no cure for DMD. The current treatment options are limited to physiotherapy and corticosteroids, and although they provide a substantial improvement in affected children, they only slow the course of the disorder. On a more optimistic note, more recent approaches either significantly alleviate or eliminate muscular dystrophy in murine and canine models of DMD and importantly, many of them are being tested in early phase human clinical trials. This review summarizes advancements that have been made in viral and nonviral gene therapy as well as stem cell therapy for DMD with a focus on the replacement and repair of the affected dystrophin gene.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23553671      PMCID: PMC4077844          DOI: 10.1002/mus.23738

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  222 in total

1.  Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors.

Authors:  H Chao; Y Liu; J Rabinowitz; C Li; R J Samulski; C E Walsh
Journal:  Mol Ther       Date:  2000-12       Impact factor: 11.454

2.  Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury.

Authors:  Mingju Liu; Yongping Yue; Scott Q Harper; Robert W Grange; Jeffrey S Chamberlain; Dongsheng Duan
Journal:  Mol Ther       Date:  2005-02       Impact factor: 11.454

3.  Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

Authors:  E A Rutledge; C L Halbert; D W Russell
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice.

Authors:  T Ragot; N Vincent; P Chafey; E Vigne; H Gilgenkrantz; D Couton; J Cartaud; P Briand; J C Kaplan; M Perricaudet
Journal:  Nature       Date:  1993-02-18       Impact factor: 49.962

5.  Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene.

Authors:  Miki Sakamoto; Katsutoshi Yuasa; Madoka Yoshimura; Toshifumi Yokota; Takaaki Ikemoto; Misao Suzuki; George Dickson; Yuko Miyagoe-Suzuki; Shin'ichi Takeda
Journal:  Biochem Biophys Res Commun       Date:  2002-05-17       Impact factor: 3.575

6.  Alternative dystrophin gene transcripts in golden retriever muscular dystrophy.

Authors:  S J Schatzberg; L V Anderson; S D Wilton; J N Kornegay; C J Mann; G G Solomon; N J Sharp
Journal:  Muscle Nerve       Date:  1998-08       Impact factor: 3.217

7.  In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state.

Authors:  Marius Wernig; Alexander Meissner; Ruth Foreman; Tobias Brambrink; Manching Ku; Konrad Hochedlinger; Bradley E Bernstein; Rudolf Jaenisch
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

8.  Dystrophin in skeletal muscle. II. Immunoreactivity in patients with Xp21 muscular dystrophy.

Authors:  L V Nicholson; K Davison; M A Johnson; C R Slater; C Young; S Bhattacharya; D Gardner-Medwin; J B Harris
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

9.  Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs.

Authors:  Y Yang; Q Su; J M Wilson
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  Restoration of dystrophin expression in mdx mice by intravascular injection of naked DNA containing full-length dystrophin cDNA.

Authors:  K W Liang; M Nishikawa; F Liu; B Sun; Q Ye; L Huang
Journal:  Gene Ther       Date:  2004-06       Impact factor: 5.250

View more
  47 in total

Review 1.  Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions.

Authors:  Suzanne E Berry
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

2.  Removing the immune response from muscular dystrophy research.

Authors:  Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2013-10       Impact factor: 11.454

3.  Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1α axis.

Authors:  Vladimir Ljubicic; Matthew Burt; John A Lunde; Bernard J Jasmin
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-23       Impact factor: 4.249

4.  Changes in calsequestrin, TNF-α, TGF-β and MyoD levels during the progression of skeletal muscle dystrophy in mdx mice: a comparative analysis of the quadriceps, diaphragm and intrinsic laryngeal muscles.

Authors:  Juliana Barros Maranhão; Drielen de Oliveira Moreira; Adriana Fogagnolo Maurício; Samara Camaçari de Carvalho; Renato Ferretti; Juliano Alves Pereira; Humberto Santo Neto; Maria Julia Marques
Journal:  Int J Exp Pathol       Date:  2015-10-30       Impact factor: 1.925

Review 5.  What do mouse models of muscular dystrophy tell us about the DAPC and its components?

Authors:  Charlotte Whitmore; Jennifer Morgan
Journal:  Int J Exp Pathol       Date:  2014-09-30       Impact factor: 1.925

6.  Extraocular muscle satellite cells are high performance myo-engines retaining efficient regenerative capacity in dystrophin deficiency.

Authors:  Pascal Stuelsatz; Andrew Shearer; Yunfei Li; Lindsey A Muir; Nicholas Ieronimakis; Qingwu W Shen; Irina Kirillova; Zipora Yablonka-Reuveni
Journal:  Dev Biol       Date:  2014-09-16       Impact factor: 3.582

Review 7.  Novel Therapies for Prevention and Early Treatment of Cardiomyopathies.

Authors:  Giuliana G Repetti; Christopher N Toepfer; Jonathan G Seidman; Christine E Seidman
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

8.  Age-dependent changes in metabolite profile and lipid saturation in dystrophic mice.

Authors:  Brittany Lee-McMullen; Stephen M Chrzanowski; Ravneet Vohra; Sean C Forbes; Krista Vandenborne; Arthur S Edison; Glenn A Walter
Journal:  NMR Biomed       Date:  2019-03-08       Impact factor: 4.044

Review 9.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

Review 10.  Recent advances using zebrafish animal models for muscle disease drug discovery.

Authors:  Lisa Maves
Journal:  Expert Opin Drug Discov       Date:  2014-06-14       Impact factor: 6.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.